Abstract: There is provided herein a combination of compound of formula (I) which is a bifunctional compound with G12D mutant KRAS inhibitory activity or a pharmaceutically acceptable salt thereof and an anti cancer agent for use in the treatment of cancer wherein the compound of formula (I) and the anti cancer agent are as described in the description.
| # | Name | Date |
|---|---|---|
| 1 | 202547020119-STATEMENT OF UNDERTAKING (FORM 3) [06-03-2025(online)].pdf | 2025-03-06 |
| 2 | 202547020119-REQUEST FOR EXAMINATION (FORM-18) [06-03-2025(online)].pdf | 2025-03-06 |
| 3 | 202547020119-PROOF OF RIGHT [06-03-2025(online)].pdf | 2025-03-06 |
| 4 | 202547020119-PRIORITY DOCUMENTS [06-03-2025(online)].pdf | 2025-03-06 |
| 5 | 202547020119-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [06-03-2025(online)].pdf | 2025-03-06 |
| 6 | 202547020119-FORM 18 [06-03-2025(online)].pdf | 2025-03-06 |
| 7 | 202547020119-FORM 1 [06-03-2025(online)].pdf | 2025-03-06 |
| 8 | 202547020119-DECLARATION OF INVENTORSHIP (FORM 5) [06-03-2025(online)].pdf | 2025-03-06 |
| 9 | 202547020119-COMPLETE SPECIFICATION [06-03-2025(online)].pdf | 2025-03-06 |
| 10 | 202547020119-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [06-03-2025(online)].pdf | 2025-03-06 |
| 11 | 202547020119-FORM-26 [07-03-2025(online)].pdf | 2025-03-07 |
| 12 | 202547020119-RELEVANT DOCUMENTS [12-03-2025(online)].pdf | 2025-03-12 |
| 13 | 202547020119-MARKED COPIES OF AMENDEMENTS [12-03-2025(online)].pdf | 2025-03-12 |
| 14 | 202547020119-FORM 13 [12-03-2025(online)].pdf | 2025-03-12 |
| 15 | 202547020119-Annexure [12-03-2025(online)].pdf | 2025-03-12 |
| 16 | 202547020119-AMMENDED DOCUMENTS [12-03-2025(online)].pdf | 2025-03-12 |
| 17 | 202547020119-FORM 3 [21-08-2025(online)].pdf | 2025-08-21 |